Search Results

OKYO Pharma Limited announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at the Dry Horizons Symposium, a partner meeting of the Association for Research in Vision and Ophthalmology, being held May 3, 2024 in Seattle, WA.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

Blackstone and Bain Capital are said to be among the final bidders for the Japanese company’s Mitsubishi Tanabe Pharma, sources told Reuters Friday.

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.

A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies including Prilenia and Wave Life Sciences eye paths to approval of therapies that could address the underlying cause of the disease.

Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the 2024 CG Horizons in Oncology Virtual Conference on Monday, April 15, 2024, at 2:00 p.m. ET.